RxDoctor Payments Data

Eva Larocque, MD

Psychiatry · Great Falls, MTNPI 1346271061

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,327 of the $1,746 with a category attached, or 76.0%. 9 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 29.9% of the total. Reporting peaked in 2019 at $497 and has fallen 65.1% since, to $174 in 2025.

$1,746in general payments, 2019–2025

Across 85 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$521
  • Johnson & Johnson$306
  • AbbVie$281
  • Otsuka America Pharmaceutical, Inc.$199
  • Neurocrine Biosciences, Inc.$177
  • Alkermes, Inc.$134
  • plus $128 from 3 others

What the payments were for

  • Food & beverage$1,32776%
  • Education$41924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,746 in reported general payments places this provider in the 85th percentile of 82 psychiatry providers in Montana.

See all psychiatry providers in Montana

Medicare billing

Part B allowed, 2024
$23,408
Medicare patients
78
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate141$452,857
AustedoDeutetrabenazine39$174,906
VraylarCariprazine Hcl265$120,119
Invega TrinzaPaliperidone Palmitate11$120,087
Abilify AsimtufiiAripiprazole14$84,671
CaplytaLumateperone Tosylate82$54,121
AristadaAripiprazole Lauroxil15$52,062
Abilify MaintenaAripiprazole19$51,933
Paliperidone ErPaliperidone343$36,282
BelsomraSuvorexant58$16,624
Aripiprazole490$15,141
Lurasidone Hcl105$14,651
Clomipramine Hcl53$11,076
Clozapine97$10,853
Olanzapine700$8,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Invega$306$575,628168 claims
Teva Pharmaceuticals USA, Inc.Austedo$521$174,90639 claims
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena$199$136,60433 claims
AbbVieVraylar$281$120,119265 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$52$54,12182 claims
Alkermes, Inc.Aristada$134$52,06215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 82 psychiatry providers in Montana.

Other psychiatry in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →